The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 27, 2021

Filed:

Jul. 20, 2018
Applicant:

Immunomedics, Inc., Morris Plains, NJ (US);

Inventors:

David M. Goldenberg, Delray Beach, FL (US);

Thomas M. Cardillo, Cedar Knolls, NJ (US);

Assignee:

Immunomedics, Inc., Morris Plains, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); C07K 16/28 (2006.01); A61K 31/4745 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61K 31/502 (2006.01); A61K 31/357 (2006.01); A61K 31/337 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 31/4184 (2006.01); A61K 31/4375 (2006.01); A61K 31/454 (2006.01); A61K 31/675 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01); A61K 33/24 (2019.01); C07K 16/30 (2006.01); A61P 35/00 (2006.01); A61K 31/513 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2833 (2013.01); A61K 31/337 (2013.01); A61K 31/357 (2013.01); A61K 31/4184 (2013.01); A61K 31/4375 (2013.01); A61K 31/454 (2013.01); A61K 31/4745 (2013.01); A61K 31/502 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 31/675 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 33/24 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6809 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6853 (2017.08); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2887 (2013.01); C07K 16/30 (2013.01); C07K 16/3007 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention relates to combination therapy with drugs, such as Bruton's tyrosine kinase inhibitors or PI3K inhibitors, with antibodies or ADCs against HLA-DR. Where ADCs are used, they preferably incorporate SN-38 or pro-2PDOX. The ADC may be administered at a dosage of between 1 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth.


Find Patent Forward Citations

Loading…